Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.
- DOI
- 10.1007/s11523-026-01237-w
- Published
- 2026 Oct 20
- Container
- Targeted oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11523-026-01237-w,
title = {Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.},
author = {Sands J and Lu S and Aerts JG and Reck M and Navarro A and Shentzer Kutiel T and Peled N and Casarini I and Kerr SJ and Takahashi T and Bilici A and Cheng Y and Wang M and Lee SY and Łowczak A and Mazieres J and Hu H and Wu J and Aggarwal H and El-Osta H and Paz-Ares L},
year = {2026},
journal = {Targeted oncology},
doi = {10.1007/s11523-026-01237-w},
url = {https://doi.org/10.1007/s11523-026-01237-w}
}RIS
TY - JOUR TI - Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer. AU - Sands J AU - Lu S AU - Aerts JG AU - Reck M AU - Navarro A AU - Shentzer Kutiel T AU - Peled N AU - Casarini I AU - Kerr SJ AU - Takahashi T AU - Bilici A AU - Cheng Y AU - Wang M AU - Lee SY AU - Łowczak A AU - Mazieres J AU - Hu H AU - Wu J AU - Aggarwal H AU - El-Osta H AU - Paz-Ares L PY - 2026 JO - Targeted oncology DO - 10.1007/s11523-026-01237-w UR - https://doi.org/10.1007/s11523-026-01237-w ER -
APA
J, S., S, L., JG, A., M, R., A, N., T, S. K., N, P., I, C., SJ, K., T, T., A, B., Y, C., M, W., SY, L., A, Ł., J, M., H, H., J, W., H, A., H, E., & L, P. (2026). Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.. Targeted oncology. https://doi.org/10.1007/s11523-026-01237-w
Source records
- pubmed · retrieved 2026-11-10T08:15:06.604Z